Corcept Therapeutics (CORT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Corcept Therapeutics (CORT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

51.63

0.57 (1.12%)

At close: Jan 14, 2025, 3:59 PM

52.03

0.78%

Pre-market Jan 15, 2025, 06:05 AM EST

undefined% (undefined)

Bid	52.2
Market Cap	5.41B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	1.26
PE Ratio (ttm)	40.97
Forward PE	n/a
Analyst	Buy

Ask	63.5
Volume	540,046
Avg. Volume (20D)	962,198
Open	51.58
Previous Close	51.06
Day's Range	50.91 - 52.55
52-Week Range	20.84 - 62.22
Beta	undefined

About CORT

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 14, 2004

Employees 352

Stock Exchange NASDAQ

Ticker Symbol CORT

Website https://www.corcept.com

Analyst Forecast

According to 4 analyst ratings, the average rating for CORT stock is "Buy." The 12-month stock price forecast is $77, which is an increase of 49.15% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Corcept Therapeutics is scheduled to release its earnings on Feb 13, 2025, during market hours.
Analysts project revenue of $198.04M, reflecting a 46.26% YoY growth and earnings per share of 0.38, making a 35.71% increase YoY.

Why Price Moved

1 month ago · Source

-6.24%

Corcept Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

2 months ago · Source

-2.74%

Corcept Therapeutics shares are trading lower. The company reported Q3 financial results.

News

2 weeks ago · zacks.com

Corcept Submits Application for Another Cushing's Syndrome Drug

CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.

2 weeks ago · businesswire.com

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...

1 month ago · businesswire.com

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes

1 month ago · zacks.com

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.

1 month ago · reuters.com

Corcept Therapeutics' ALS drug fails in mid-stage trial

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.

1 month ago · businesswire.com

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

1 month ago · zacks.com

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 month ago · zacks.com

Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why

Corcept (CORT) could produce exceptional returns because of its solid growth attributes.

1 month ago · zacks.com

Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?

The consensus price target hints at a 26.1% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

1 month ago · zacks.com

What Makes Corcept (CORT) a Good Fit for 'Trend Investing'

Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 month ago · zacks.com

Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

1 month ago · seekingalpha.com

Corcept Therapeutics: A Most Promising And Compelling Biotech

Corcept Therapeutics specializes in cortisol-modulating drugs, with Korlym targeting Cushing Syndrome and a promising pipeline, including Relacorilant, for diabetes and ovarian cancer. CORT's robust f...

1 month ago · zacks.com

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

1 month ago · zacks.com

Corcept Shares Rise More Than 60% in Three Months: Here's Why

CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.

1 month ago · zacks.com

3 Reasons Growth Investors Will Love Corcept (CORT)

Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

1 month ago · zacks.com

Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positi...

1 month ago · zacks.com

Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable

Corcept (CORT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our ...

2 months ago · zacks.com

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

2 months ago · zacks.com

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

2 months ago · zacks.com

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Investors target stocks that are witnessing a bull run. Some of the stocks seeing price strength are CDXC, SEZL, TILE, BGC, CORT.

Load More News